Co-Authors
This is a "connection" page, showing publications co-authored by Sergio Bernardini and Massimo Pieri.
Connection Strength
3.970
-
Serum Amyloid A Protein as a useful biomarker to predict COVID-19 patients severity and prognosis. Int Immunopharmacol. 2021 Jun; 95:107512.
Score: 0.932
-
Clinical validation of a second generation anti-SARS-CoV-2 IgG and IgM automated chemiluminescent immunoassay. J Med Virol. 2021 04; 93(4):2523-2528.
Score: 0.926
-
SARS-CoV-2 infection serology validation of different methods: Usefulness of IgA in the early phase of infection. Clin Chim Acta. 2020 Dec; 511:28-32.
Score: 0.905
-
Evaluation of S-RBD and high specificity ACE-2-binding antibodies on SARS-CoV-2 patients after six months from infection. Int Immunopharmacol. 2021 Oct; 99:108013.
Score: 0.240
-
Performance of a rapid antigen test in the diagnosis of SARS-CoV-2 infection. J Med Virol. 2021 May; 93(5):2988-2991.
Score: 0.232
-
Evaluation of a new simultaneous anti-SARS-CoV-2 IgA, IgM and IgG screening automated assay based on native inactivated virus. Int Immunopharmacol. 2021 Mar; 92:107330.
Score: 0.230
-
Combined anti-SARS-CoV-2 IgA, IgG, and IgM Detection as a Better Strategy to Prevent Second Infection Spreading Waves. Immunol Invest. 2022 Feb; 51(2):233-245.
Score: 0.226
-
SARS-CoV-2 infection serology: a useful tool to overcome lockdown? Cell Death Discov. 2020; 6:38.
Score: 0.221
-
Low Vitamin D Status at Admission as a Risk Factor for Poor Survival in Hospitalized Patients With COVID-19: An Italian Retrospective Study. J Am Coll Nutr. 2021 Feb 18; 1-16.
Score: 0.058